MGTX Stock Analysis: MeiraGTx Holdings | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.289m USD | 12M Return: 89.4% | Charts, Fundamentals & Technical Analysis

Gene Therapy, Ocular Treatments, Neurodegenerative Therapies, Cell Therapy
Total Rating 37
Safety 32
Buy Signal 0.43
Biotechnology
Industry Rotation: +30.9
Market Cap: 1.29B
Avg Turnover: 10.3M
Risk 3d forecast
Volatility71.2%
VaR 5th Pctl11.8%
VaR vs Median0.63%
Reward TTM
Sharpe Ratio1.31
Rel. Str. IBD94.4
Rel. Str. Peer Group67.8
Character TTM
Beta1.724
Beta Downside1.773
Hurst Exponent0.498
Drawdowns 3y
Max DD49.93%
CAGR/Max DD0.60
CAGR/Mean DD1.50
EPS (Earnings per Share) EPS (Earnings per Share) of MGTX over the last years for every Quarter: "2021-06": -0.46, "2021-09": -0.59, "2021-12": -0.22, "2022-03": -0.7, "2022-06": -0.76, "2022-09": -0.83, "2022-12": -0.6, "2023-03": -0.62, "2023-06": -0.53, "2023-09": -0.74, "2023-12": -0.42, "2024-03": -0.32, "2024-06": -0.76, "2024-09": -0.55, "2024-12": -0.5, "2025-03": -0.51, "2025-06": -0.48, "2025-09": -0.62, "2025-12": 0.19, "2026-03": -0.57,
Last SUE: -0.38
Qual. Beats: 0
Revenue Revenue of MGTX over the last years for every Quarter: 2021-06: 5.116, 2021-09: 6.947, 2021-12: 21.043, 2022-03: 5.633, 2022-06: 10.759, 2022-09: 4.816, 2022-12: -5.288, 2023-03: 3.334, 2023-06: 3.54, 2023-09: 5.103, 2023-12: 2.04, 2024-03: 0.697, 2024-06: 0.282, 2024-09: 10.91, 2024-12: 21.39, 2025-03: 1.926, 2025-06: 3.691, 2025-09: 0.41, 2025-12: 75.364, 2026-03: 0.293,
Rev. CAGR: 152.27%
Rev. Trend: 93.1%
Last SUE: -0.62
Qual. Beats: 0

Warnings

Negative Equity With Losses: Insolvent Profile
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Overextended 3d

Tailwinds

Rs Leader
Tailwind
Pullback 52w

Seasonality 8 years of data

Jan -6.2% 23
Feb +1.4% 9
Mar -4.8% 24
Apr +1.7% 21
May +2.4% 9
Jun +0.4% 0
Jul +12.9% 11
Aug -8.2% 10
Sep +3.1% 26
Oct -3.8% 6
Nov +9.4% 7
Dec +6.2% 10

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: MGTX MeiraGTx Holdings

MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing gene therapies for serious diseases, with its lead programs targeting ocular disorders, neurodegenerative conditions, and xerostomia. Its clinical pipeline spans multiple Phase 1/2 and Phase 2 trials-including AAV-AQP1 for radiation-induced xerostomia and Sjogrens syndrome, AAV-GAD for Parkinsons disease, AAV-RPE65 for RPE65-associated retinal dystrophy, and AAV-CNGB3/AAV-CNGA3 for achromatopsia-while preclinical work addresses additional inherited retinal diseases, amyotrophic lateral sclerosis, Alzheimers disease, and age-related macular degeneration. The company also operates a riboswitch platform for metabolic peptide delivery and a cell therapy program aimed at oncology, autoimmune disease, and intractable pain.

The business model relies on a partnership-driven approach, with notable collaborations including Johnson & Johnson Innovative Medicine for inherited retinal disease gene therapies and Hologen Limited for CNS-focused programs such as AAV-GAD (Parkinsons) and AAV-BDNF (genetic obesity). Founded in 2015 and headquartered in New York, MeiraGTx is classified within the Biotechnology sub-industry, a sector where pre-revenue companies typically depend on capital raises, milestone payments, and strategic alliances to fund costly late-stage clinical development before reaching commercialization.

Headlines to Watch Out For
  • Johnson & Johnson partnership catalyzes retinal gene therapy milestones
  • Phase 2 readouts pending across AAV-AQP1 xerostomia and AAV-GAD Parkinson programs
  • In-house GMP manufacturing supports clinical supply and partnership economics
Piotroski VR-10 (Strict) 3.0
Net Income: -120.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.01 > 0.02 and ΔFCF/TA 47.95 > 1.0
NWC/Revenue: -100.2% < 20% (prev 79.74%; Δ -180.0% < -1%)
CFO/TA 0.03 > 3% & CFO 8.28m > Net Income -120.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 0.55 > 1.5 & < 3
Outstanding Shares: last quarter (81.3m) vs 12m ago 2.87% < -2%
Gross Margin: 91.64% > 18% (prev 17.73%; Δ 73.91% > 0.5%)
Asset Turnover: 34.04% > 50% (prev 15.40%; Δ 18.63% > 0%)
Interest Coverage Ratio: -9.04 > 6 (EBIT TTM -108.5m / Interest Expense TTM 12.0m)
Altman Z'' -15.00
A: -0.33 (Total Current Assets 96.2m - Total Current Liabilities 176.1m) / Total Assets 244.7m
B: -3.53 (Retained Earnings -862.5m / Total Assets 244.7m)
C: -0.46 (EBIT TTM -108.5m / Avg Total Assets 234.3m)
D: -0.19 (Book Value of Equity -58.1m / Total Liabilities 302.8m)
Altman-Z'' = -16.95 = D
Beneish M -2.51
DSRI: 1.49 (Receivables 18.0m/5.22m, Revenue 79.8m/34.5m)
GMI: 0.19 (GM 17.73% / 91.64%)
AQI: 0.94 (AQ_t 0.04 / AQ_t-1 0.05)
SGI: 2.31 (Revenue 79.8m / 34.5m)
TATA: -0.53 (NI -120.5m - CFO 8.28m) / TA 244.7m)
Beneish M = -2.51 (Cap -4..+1) = A
What is the price of MGTX shares?

As of July 08, 2026, the stock is trading at USD 14.66 with a total of 1,947,281 shares traded. Over the past week, the price has changed by +16.91%, over one month by +61.28%, over three months by +54.15% and over the past year by +89.41%.

Current recommended Stop Loss: 13.70 (which is 6.5% or 1.3 ATR below the current price).

Is MGTX a buy, sell or hold?

MeiraGTx Holdings has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MGTX.

  • StrongBuy: 3
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the MGTX price?
Analysts Target Price 28.3 92.7%
MeiraGTx Holdings (MGTX) - Fundamental Data Overview as of 07 July 2026
Market Cap USD = 1.29b (1.29b USD * 1.0 USD.USD)
P/E Forward = 1.6147
P/S = 16.1629
P/B = 228.2969
Revenue TTM = 79.8m USD
EBIT TTM = -108.5m USD
EBITDA TTM = -95.7m USD
Long Term Debt = 49.7m USD (from longTermDebt, last quarter)
Short Term Debt = 27.1m USD (from shortTermDebt, last quarter)
Debt = 100.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.0m
Net Debt = 29.0m USD (calculated: Debt 100.5m - CCE 71.5m)
Enterprise Value = 1.32b USD (1.29b + Debt 100.5m - CCE 71.5m)
Interest Coverage Ratio = -9.04 (Ebit TTM -108.5m / Interest Expense TTM 12.0m)
EV/FCF = -562.6x (Enterprise Value 1.32b / FCF TTM -2.34m)
FCF Yield = -0.18% (FCF TTM -2.34m / Enterprise Value 1.32b)
FCF Margin = -2.94% (FCF TTM -2.34m / Revenue TTM 79.8m)
Net Margin = -151.1% (Net Income TTM -120.5m / Revenue TTM 79.8m)
Gross Margin = 91.64% ((Revenue TTM 79.8m - Cost of Revenue TTM 6.67m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 5.39 (Enterprise Value 1.32b / Total Assets 244.7m)
Interest Expense / Debt = 11.94% (Interest Expense 12.0m / Debt 100.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -85.7m (EBIT -108.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.55 (Total Current Assets 96.2m / Total Current Liabilities 176.1m)
 Debt / Equity = -1.73 (negative equity) (Debt 100.5m / totalStockholderEquity, last quarter -58.1m)
 Debt / EBITDA = -0.30 (negative EBITDA) (Net Debt 29.0m / EBITDA -95.7m)
 Debt / FCF = -12.36 (negative FCF - burning cash) (Net Debt 29.0m / FCF TTM -2.34m)
 Total Stockholder Equity = -25.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -51.44% (Net Income -120.5m / Total Assets 244.7m)
 RoE = 474.9% (negative equity) (Net Income TTM -120.5m / Total Stockholder Equity -25.4m)
 RoCE = -446.3% (out of range, set to none) (EBIT -108.5m / Capital Employed (Equity -25.4m + L.T.Debt 49.7m))
 RoIC = -93.53% (negative operating profit) (NOPAT -85.7m / Invested Capital 91.7m)
 WACC = 11.86% (E(1.29b)/V(1.39b) * Re(12.05%) + D(100.5m)/V(1.39b) * Rd(11.94%) * (1-Tc(0.21)))
Discount Rate = 12.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 11.53%
 [DCF] Fair Price = unknown (Cash Flow -2.34m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.38 | # QB: 0
Revenue Correlation: 93.14 | Revenue CAGR: 152.3% | SUE: -0.62 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.25 | Chg30d=+62.57% | Revisions=+29% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.50 | Chg30d=+19.68% | Revisions=+50% | Analysts=5
EPS current Year (2026-12-31): EPS=-1.47 | Chg30d=+4.24% | Revisions=+50% | GrowthEPS=-3.3% | GrowthRev=-39.0%
EPS next Year (2027-12-31): EPS=-1.39 | Chg30d=+4.02% | Revisions=+57% | GrowthEPS=+5.1% | GrowthRev=+95.9%
[Analyst] Revisions Ratio: +71% (up=13, down=1)